The quarterly report is in my opinion very disappointing.
I think it highlights that sales of Evolis have been disappointing and that re-orders are not happening. There are several thoughts here which may be applicable. The product is not being advertised and supported by the seller, or not effective (it has to be considered as a possibility before you start to shoot at me) or is priced at a level where those who want (need) it can't afford to buy it.
I will patiently will wait for the next quarterly results. I hope that my view is wrong that sales go gangbusters.
CDY Price at posting:
2.1¢ Sentiment: None Disclosure: Held
